عنوان مقاله :
Effects of Imfluna, an Iranian traditional polyherbal medicine, on COVID-19 symptoms: A randomized, double-blind and placebo-controlled clinical trial
پديد آورندگان :
Fallah Huseini ، Hasan ACECR - Medicinal Plants Research Center, Institute of Medicinal Plants , Gholibeikian ، Mohammadreza University of Kashan - Faculty of Chemistry - Department of Organic Chemistry , Shohrati ، Majid Baqiyatallah Uiversity of Medical Sciences - Faculty of Pharmacy - Department of Pharmacotherapy , Kaffash ، Afsaneh Sabzevar University of Medical Sciences - Faculty of Medicine - Department of Internal Medicine , Taheri ، Ali Baqiyatallah University of Medical Sciences - Faculty of Pharmacy , Khajepour ، Hojatolah Baqiyatallah University of Medical Sciences - Department of Radiology , Raei ، Mehdi Baqiyatallah University of Medical Sciences - Health Research Center, Life Style Institute , Kianbakht ، Saeed ACECR - Medicinal Plants Research Center, Institute of Medicinal Plants , Fallah Hosseini ، Amena Tehran University of Medical Sciences - Department of Emergency Medicine , Ghorbani Nohooji ، Majid ACECR - Medicinal Plants Research Center, Institute of Medicinal Plants , Mohtashami ، Reza Baqiyatallah University of Medical Sciences - Medicine Quran and Hadith Research Center
كليدواژه :
Clinical trial , COVID , 19 , Polyherbal medicine , Iranian traditional , medicine , Imfluna ,
چكيده فارسي :
Background: The current pandemic of Coronavirus disease 2019 (COVID19) and severity of the infection and high mortality have almost unprecedented challenges in the health systems of most countries around the world. Objective: The present study aimed to evaluate the effect of Iranian traditional polyherbal medicine (Imfluna) containing a mixture of echinacea, stachys, artemisia, hyssopus, polybody, alpinia, ginger, and ginseng extract on symptoms of COVID19 infected patients. Methods: In this placebocontrolled and doubleblind clinical trial, a total of 60 voluntarily approved patients with COVID19 were randomly assigned to the placebo and Imfluna groups. Patients in each group, in addition to receiving standard medications, took two 500 mg capsules of Imflona or placebo every 8 hours for 2 weeks. The patient #39;s vital signs, including the severity of shortness of breath, cough, and body temperature, were recorded during the study. Also blood ESR, liver and kidney function tests were performed at baseline and endpoint. Results: The results showed that patients in the Imflunatreated group had significantly greater improvement in daily cough, shortness of breath and ESR compared with the placebo group. In addition, lung lesions improved in the Imflunatreated group, although not significantly. Conclusion: Patients with COVID19 who were treated with Imfluna for 2 weeks had better comfort and fewer symptoms associated with the disease with no any drug side effects.
عنوان نشريه :
گياهان دارويي
عنوان نشريه :
گياهان دارويي
